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Hepatocellular carcinoma (HCC) treated with trans-arterial chemoembolization (TACE) can
later show areas of hepatocellular or cholangiocarcinoma (CC) differentiation. Biomarkers
are  required to deﬁne details in phenotype/pathogenesis of these HCC/CC regions, and sim-
ilarities to their normal and classic counterparts. Proteins from laser microdissected FFPE
tissue  were in-gel digested and peptides analyzed by nano-HPLC–MS/MS. We  identiﬁed 95
proteins with signiﬁcant differential expression between HCC vs. CC regions. We  also found
signiﬁcant differences in other tissue type comparisons. Some protein biomarkers are being
reported  here for the ﬁrst time in the context of liver carcinogenesis and may  be clinically
useful.Trans-arterial  chemo-embolization
Hepatocellular carcinoma
Cholangiocellular carcinoma
Mass  spectrometry
Nano-HPLC
©  2013 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). Open access under CC BY-NC-ND license.1.  IntroductionPrimary liver tumors are classiﬁed into epithelial, mesenchy-
mal,  germ cell, lymphoid and of mixed or uncertain origin
Abbreviations: AUC, area under the curve; CC, cholangiocellular car
lular carcinoma; IHC, immunohistochemistry; LMD, laser microdissec
match; TACE, trans-arterial chemo-embolization.
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2212-9685 © 2013 The Authors. Published by Elsevier B.V. on behalf of European Proteo
http://dx.doi.org/10.1016/j.euprot.2013.10.001according to the latest WHO  classiﬁcation [1]. Epithelialcinoma; FFPE, formalin ﬁxed parafﬁn embedded; HCC, hepatocel-
tion; PSC, primary sclerosing cholangitis; PSM, peptide spectrum
tumors are the commonest, and generally divided into hepa-
tocellular  and cholangiocellular due to their phenotypic
similarity to hepatocytes and biliary epithelium, respectively
and  presumed derivation. Hepatocellular carcinoma (HCC)
mics Association (EuPA). Open access under CC BY-NC-ND license.
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nd cholangiocarcinoma (CC) are the most common malig-
ant types. HCC is the ﬁfth most common cancer worldwide,
nd usually develops in the context of chronic liver disease [2].
C can arise from any portion of the intrahepatic biliary tree,
nd is classiﬁed into peripheral and hilar/perihilar based on
he predominant location, probable different biological char-
cteristics, and pathogenesis. This classiﬁcation is supported
y an association with risk factors such as viral hepatitis or
lcoholic liver disease in peripheral CC. In contrast, multi-step
arcinogenesis through intraepithelial neoplasia often in the
ontext of a chronic cholangiopathy (e.g. primary sclerosing
holangitis (PSC)) appears to be behind the development of
ilar/perihilar CC [3].
Some primary carcinomas show a mixed phenotype, with
reas of hepatocellular differentiation alternating with areas
f cholangiocellular differentiation. An origin from hepatic
rogenitor cells has been proposed for these tumors, on the
roader basis of the cancer stem cell theory that all primary
iver tumors and in particular the epithelial ones may be part
f a phenotypic spectrum with “pure” HCC and CC at either
nd, and mixed cancers somewhere in the middle [4,5]. In this
espect, we  reported recently that local ablation therapy with
ransarterial chemoembolization (TACE) is associated with
holangiocellular differentiation in HCC [6]. A potential expla-
ation for this observation is that TACE provides selection
ressure in favor of a minor progenitor cell population that
s resistant to TACE and capable of multipotent differentiation
ncluding biliary lineage. The hepatocellular and cholangio-
ellular/progenitor cell components were identiﬁed by single
r double immunostainings or gene expression analysis (RT-
CR) from microdissected tissue, using a relatively limited
umber of known conventional markers [6]. More markers
re required to help better deﬁne the details of the pheno-
ype and pathogenesis of the different HCC/CC components of
ost-TACE tumors, their similarities to their normal and typ-
cal malignant counterparts, and aid in diagnosis, prognosis
nd potentially identify new selective therapeutic targets and
redictive markers.
Liquid chromatography–mass spectrometry (LC–MS/MS)
ased proteomics has proven to be superior over conven-
ional biochemical methods at identifying and quantifying
housands of proteins from complex samples including cul-
ured cells and clinical tissue [7,8]. Particular focus has been
ut into the application of mass spectrometry based pro-
eomic analysis on formalin ﬁxed parafﬁn embedded (FFPE)
issue because of the enormous collections of highly char-
cterized FFPE tissue derived from both human and model
rganisms throughout the world [9,10]. We too chose FFPE
issue to have access to a sufﬁcient number of archival infor-
ative cases from normal and tumor tissue. Due to the
haracteristic heterogeneity of the tumors and the fact that
nformative areas can be very focal, the use of frozen tissue
amples usually of small size could result in a low yield of
epresentative cases and is therefore not ideal.
Large scale global proteomic analysis of laser microdis-
ected FFPE tissue has been successfully employed to discover
ifferentially expressed proteins between different histologi-
al tissue types and thus successfully discovered novel protein
iomarkers of disease [10–13]. Many  of these studies utilized
abel free quantitative strategies, such as spectral counting 1 ( 2 0 1 3 ) 38–47 39
and signal intensities of peptide precursor ions, both
approaches beneﬁting from reduced spectral complexity and
more analytical depth as well as good linear dynamic range
(over two orders of magnitude for spectral counting) and high
quantitative proteome coverage [11–15].
In this study we combined laser microdissection of speciﬁc
FFPE tissue types with liquid chromatography–mass spec-
trometry based proteomics, utilizing label free quantiﬁcation.
We identiﬁed proteins that demonstrate statistically signiﬁ-
cant differences in expression between different components
(HCC and CC) of post-TACE HCC and explored their similari-
ties or dissimilarities to their normal and typical malignant
counterparts. We  also found signiﬁcant differences in other
tissue type comparisons. These differentially expressed pro-
teins may be useful biomarkers to help diagnose tumor types
and assess patient prognosis.
2.  Materials  and  methods
2.1.  Liver  tissue
This study was approved by the Ethical Committee of King’s
College Hospital, London. This study consists of 9 types of
liver tissue taken from a total of 55 archived specimens:
mixed HCC/CC after TACE (areas of HCC and areas of CC sepa-
rately examined), non-treated HCC, normal liver parenchyma,
normal bile duct, non-treated peripheral CC, non-treated
hilar/perihilar CC, PSC-associated hilar CC, and metastatic
colorectal cancer. All specimens were surgically resected or
explanted livers from adult patients ranging from 27 to 80
years in age. Details of tissues in each group are as follows:
• Mixed  cancer after TACE (n = 7): Before the treatment with
TACE, all nodules were radiologically diagnosed as HCC
according to European Association for the Study of the Liver
(EASL) criteria of concordant imaging of nodular arterial-
ized lesions with portal venous washout [16]. The presence
of features suggestive of combined HCC and CC and in
particular hypoarterialization was a criterion of exclusion
for TACE. In explanted livers, cholangiocellular differenti-
ation in addition to HCC components was histologically
suggested. HCC and CC components were separately exam-
ined.
• HCC (n = 7): Well to moderately differentiated HCCs, which
did not receive any treatment before transplantation,
arranged in a trabecular or pseudoglandular pattern and
developed in cirrhotic livers were examined. Etiologies of
liver cirrhosis were viral hepatitis (n = 3) and excessive alco-
holic intake (n = 4). One tumor was selected from each case
when multiple tumors were present.
• Normal liver tissue (n = 7): Histologically unremarkable liver
tissues without steatosis, inﬂammation, or ﬁbrosis were
selected from specimens that were surgically resected for
metastatic cancers.
• Normal bile duct (n = 6): Histologically unremarkable hilar
bile ducts are selected from liver specimens that weredose.
• Peripheral CC (n = 7): All cases showed well to moder-
ately differentiated tubular adenocarcinoma against the
o m i c40  e u  p a o p e n p r o t e 
background of ﬁbrotic stroma. Hilar or perihilar tissue was
not involved in any cases. The background liver was not cir-
rhotic in any cases, but two had early bridging ﬁbrosis with
moderate steatosis.
• Hilar CC (n = 7): All were ductal adenocarcinoma predomi-
nantly involving hilar/perihilar bile ducts. No patients had
histories of chronic hepatobiliary diseases.
• PSC-associated CC (n = 7): Four cases were diagnosed to
have CCs during treatment for PSC and underwent surgical
resection, whereas three were incidentally found to have CC
in explanted livers. All tumors were histologically adeno-
carcinoma, four associated with mucinous foci, which are
sometimes seen in PSC-associated CC.
• Metastatic colorectal cancer (n = 7): All were typical intesti-
nal type adenocarcinoma.
2.2.  Tissue  sampling
Fresh liver specimens, which were surgically resected, were
immediately received at our pathology laboratory. After
macroscopic examination, samples were extensively taken,
and were ﬁxed in 10% formalin for at least 4 h before being
embedded in parafﬁn.
2.3.  Microdissection  of  FFPE  tissue
10 m thick sections were prepared from FFPE tissue blocks.
After deparafﬁnization with xylene and alcohol, a target area
of 1.5 × 107 m2 (0.15 mm3) was selectively cut using the Laser
Capture Microdissection System (LMD6500, Leica Microsys-
tems, Wetzlar, Germany). Dissected tissues were directly
immersed in 50 L of Qproteome® FFPE Tissue Extraction
Buffer (QIAGEN, Valencia, CA) and stored in −80 ◦C until pro-
tein extraction. Samples were prepared in batches, e.g. week
1 (batch 1) the 1st biological replicate of each tissue/tumor
type were prepared and analyzed. At week 2 (batch 2), the
2nd biological replicates of each tissue/tumor type were pre-
pared and analyzed. This process was continued up until
week 7 (batch 7) where the 7th biological replicate of each tis-
sue/tumor type were prepared and analyzed. Samples were
prepared and analyzed in this way to ensure that differences
in protein expression levels between different tissue types
were due to biology/pathology of the sample, rather than any
sample preparation variability.
2.4.  Protein  extraction  from  FFPE  liver  tissue
Following storage at −80 ◦C samples were thawed on ice then
homogenized, vortexed and centrifuged. Samples were trans-
ferred to 1.5 ml  collection tubes and sealed with collection tube
sealing clip, as provided in the Qproteome® kit. Samples were
incubated on a heating block at 100 ◦C for 20 min, then for a
further 2 h at 80 ◦C with agitation at 750 rpm. After heating,
the sample tubes were placed on ice for 1 min  and the col-
lection tube sealing clip removed. Each tube was centrifuged
◦for 15 min  at 14,000 × g at 4 C. The supernatant were then
transferred to a new siliconised collection tube. The protein
concentration of each sample were then determined using the
Bradford protein assay and microplate luminometer. s 1 ( 2 0 1 3 ) 38–47
2.5.  1D  electrophoresis  gels
Stacking gels were constructed to comprise a 1 cm height 4%
(w/v) polyacrylamide matrix on top of a 20% (w/v) polyac-
rylamide matrix. Protein samples and pre-stained molecular
weight markers were each prepared in Sigma 2× Laemmli
sample buffer (1:1) and run into the gels in Tris–glycine run-
ning buffer (Invitrogen, Loughborough, UK) for 20 min  at 150 V,
or until the protein sample and molecular weight markers
were observed to concentrate at the 4–20% w/v  gel interface.
Each sample was loaded onto the gel at 100 g/well. Following
electrophoresis the gels were brieﬂy stained with Imperial pro-
tein stain (Pierce, IL, USA) then de-stained in water to visualize
the proteins and to conﬁrm their migration as a homogeneous
population. The protein band visible at the 4–20% (w/v) gel
interface was excised from each lane.
For separation gels we used the 1 mm thick 10 well Nu-PAGE
4–12% bis–tris gels from Invitrogen, Carlsbad, CA, USA.
2.6.  Reduction/alkylation/trypsin  digestion
Gel bands were chopped into small 1 mm3 pieces then
destained and dehydrated with ACN. Proteins were sub-
sequently reduced with 10 mM dithiothreitol in 25 mM
ammonium bicarbonate at 56 ◦C for 1 h and alkylated with
55 mM iodoacetamide in 25 mM ammonium bicarbonate at
room temperature for 45 min. Gel pieces were then washed,
dried, rehydrated on ice for 10 min  in 2 g of sequence
grade trypsin, reconstituted in 100 L of 25 mM ammonium
bicarbonate, then covered with an additional 20 L ammo-
nium bicarbonate solution, and incubated overnight at 37 ◦C.
The resulting proteolytic peptides were subjected to aque-
ous (30 L ammonium bicarbonate, 20 min  vortex) and two
hydrophobic extractions (100 L of 50% ACN, 5% formic acid,
20 min  vortex, 10 min  sonication). Samples were quickly vor-
texed and centrifuged then frozen to −80 ◦C. The frozen
sample were then concentrated under vacuum to ∼20 L, then
topped up with 0.1% Formic acid to 70 L, gel particulates ﬁl-
tered out using 30000 MW ﬁlters (Millipore), and ﬁnally stored
at −80 ◦C until used for LC–MS/MS.
2.7.  Liquid  chromatography–mass  spectrometry
(LC–MS/MS)
After freeze/thaw, 10 L of each sample were injected onto
a Thermo pre-column (EASY-Column, 2 cm,  ID 100 m,  5 m
C18-A1), using the Proxeon EASY-nLC II system (Thermo Fisher
Scientiﬁc). Peptides were then resolved using an increasing
gradient of 0.1% formic acid in acetonitirile (5–50% over 80 min)
through a Thermo analytical column (EASY-Column, 10 cm, ID
75 m,  3 m C18-A2) at a ﬂow rate of 300 nL/min. Mass spectra
were acquired on an LTQ Orbitrap Velos (Thermo Fisher Sci-
entiﬁc) throughout the chromatographic run (115 min), using
20× CID scans following each FTMS scan (2×  Scans at 30,000
resolving power @ 400 m/z). CID was carried out on 20 of the
most intense ions from each FTMS scan then put on a dynamic
exclusion list for 30 s (20 ppm m/z window). AGC ion injection
target for each FTMS scan were 1,000,000 (500 ms  max injec-
tion time). AGC ion injection target for each MSA  CID scan were
10,000 (50 ms  max  ion injection time).
e u  p a o p e n p r o t e o m i c s
Fig. 1 – Data analysis. Overall data analysis workﬂow used
prior to the statistical analysis. The two data quantiﬁcation
methods that were  implemented; area under the curve
(AUC) in red-blocks and spectral counting in yellow blocks
generated data matrices that were  used for further
statistical analysis. The ﬁnal list was obtained for proteins
that were common to both quantiﬁcation methods and
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.8.  Data  pre-processing
.8.1.  Peptide  identiﬁcation
eak lists were extracted from Xcalibur Raw data ﬁle for-
at  using Proteome Discoverer 1.4 which were then searched
sing Mascot 2.2 and Sequest HT Search engines. Fig. 1
llustrates the overall workﬂow used for peptide identiﬁca-
ion and quantiﬁcation. The spectrum ﬁles node was used
o select the raw data ﬁles of interest. Spectrum selector
ode was set to its default values, therefore the data was
ot smoothed, no signal to noise threshold was set, and no
harge state ﬁltering or de-isotoping took place. Both Mascot
nd Sequest Nodes, were set up to search data against the
niProtKB/Swiss-Prot database (uniprot sprot.fasta, down-
oaded from http://www.uniprot.org/downloads 20th February
013), taxonomy Homo-sapiens (human). These nodes were
rogrammed to search for tryptic peptides with up to 2 missed
leavages (C-Term K/R restrict P), with static modiﬁcations set
s carbamidomethyl (C). Dynamic modiﬁcations were set to
eamidation (N/Q), oxidation (M). Precursor mass tolerance
as set to 10 ppm and fragment mass tolerance 0.5 Da for
oth data base search engines. Once peptides were identiﬁed
sing each of the two search methods, the Percolator node
ltered identiﬁcations of basis of q-values which were esti-
ated on the basis of the target-decoy search approach. To
lter out target peptide spectrum matches (target-PSMs) over
he decoy-PSMs a ﬁxed false discovery rate (FDR) of 1% was
et at the peptide level. The protein ﬁlter ‘Peptides per Pro-
ein’ option was set to 2. Both ‘Count only rank 1 peptides’ 1 ( 2 0 1 3 ) 38–47 41
and ‘Count peptide only in top scored proteins’ were set as
active. This ensured the Protein level stringency.
2.8.2.  Protein  quantiﬁcation
For each of the 62 tissue specimen data ﬁles (n = 7 for 8 of the
tissue types, n = 6 for normal bile duct), Proteome Discover 1.4
was used to export the list of identiﬁed proteins to excel. For
quantiﬁcation purposes we utilized the node ‘The Precursor
Ions Area Detector’ of Proteome Discoverer 1.4 which calcu-
lates the area under the curve (AUC) of each precursor ion
using integration. For greater accuracy, it uses an average of
the three most abundant peptides per protein rather than all
peptides per protein to calculate the protein area. The num-
ber of PSMs for each protein in each sample was also used for
quantiﬁcation (spectral counting). We exported a table from
Proteome Discoverer that contained uniprot accession num-
bers, protein names, the number of peptide spectrum matches
and the protein area for each protein from each sample ﬁle.
Both number of spectral counts and protein area estimates
for each protein in each sample were used for further statisti-
cal validation. Unmodiﬁed/Modiﬁed and shared (homologous)
peptides were also present in the output list from Proteome
Discoverer. Dynamic exclusion was set to 30 s.
2.8.3.  Normalization
Both spectral counts and AUC for each protein from each sam-
ple were normalized to compensate for any artifact differences
between samples such as unequal loading of protein onto
the gel wells, variable peptide extraction from the gel pieces,
and variable injection amounts into the LC–MS/MS system.
The protein area estimates were log10 transformed prior to
normalization. Normalization was done using the following
equation:
N =
[
p∑
n/x˜
]
where N is the normalized value for each protein in each sam-
ple; p is the un-normalized value for each protein in each
sample;
∑
n is the total number of PSMs or the total log10
transformed protein area per LC–MS/MS analysis; x˜ is the
median value of
∑
n of all the LC–MS/MS analyses.
2.9.  Statistical  analysis
Principal component analysis (PCA) was performed to inves-
tigate the multivariate datasets and identify outliers and
groups/clusters nested within the datasets. Normalized pro-
tein values were used for PCA, which was performed using
Simca v. 11, MKS Umetrics AB, Sweden [17].
Hierarchical clustering to build a class hierarchy for tissue
types in relation to normalized protein values and statistical
analyses to observe differential regulation of proteins between
tissue-types were carried out in MATLAB: The MathWorks Inc.
(R2012a) [18]. Two types of hierarchical clustering were per-
formed to group the normalized protein abundances using
agglomerative based clustering. The ﬁrst hierarchical clus-
tering was based on Pearson’s correlation coefﬁcients. The
Pearson’s correlation coefﬁcients were obtained by compar-
ing all normalized protein levels in all the samples (62) across
all other samples (62), which resulted in a square data matrix
o m i c42  e u  p a o p e n p r o t e 
consisting of 62 × 62 r2 Pearson’s correlation coefﬁcients. The
second clustering was performed using ‘city-block’ distance
metric (also known as the Manhattan distance) with un-
weighted average distance (UPGMA) linkage to generate a hier-
archical tree. The process clustered all data points ﬁrst along
all the columns (producing row-clustered data), and then
along all the rows in the data matrix where rows corresponded
to proteins and columns corresponded to the samples.
For each of the between group (tissue type) comparisons
unpaired t-tests were performed for each protein to obtain
signiﬁcance level estimates (p-values) from the protein
expression data matrix that consisted of normalized protein
areas or normalized Spectral Counts (number of PSMs). A pro-
tein was considered to be differentially modulated between
the two tissue types when it had a p-value <0.05, log2 fold
ratio >2 or log2 fold ratio <−2. Volcano plots were created
using these p-values and log2 fold changes as described by
Cui et al. and Best et al. [19,20].
2.10.  Immunohistochemistry  (IHC)
Four tissue types (normal liver (n = 7), normal bile duct (n = 6),
HCC (n = 7), and peripheral CC (n = 7)) were used for validation
IHC, as these are clinically most important to differentiate.
One representative section selected from each case was used
for immunostaining. Sections for IHC were taken from the
same cases that were analyzed by LC–MS. Immunostaining
on FFPE specimens was performed using an autostainer Bond
Max  (Leica Microsystems, Wetzlar, Germany). The deparaf-
ﬁnized sections were heat-treated in a pH 6.0 buffer for 10 min.
The primary monoclonal antibodies used were anti-AKR1B10
(clone 1A6; 1:500; Abcam, Cambridge, UK) and anti-tubulin
beta 3 (clone TU20; 1:500; Abcam).
2.11.  Tissue  type  number  key
(1) = Normal liver epithelium (Hepatocytes).
(2) = Hepatocellular carcinoma.
Combined hepato-cholangiocellular carcinoma after TACE
therapy i.e.
(3) = areas of hepatocellular differentiation, and
(4) = areas of cholangiocellular differentiation.
(5) = Peripheral (intrahepatic) cholangiocarcinoma.
(6) = Hilar cholangiocarcinoma originated in patients without
primary sclerosing cholangitis.
(7) = Hilar cholangiocarcinoma originated in patients with
primary sclerosing cholangitis.
(8) = Metastatic colo-rectal carcinoma.
(9) = Normal biliary epithelium (Cholangiocytes).
3.  Results
3.1.  Protein  identiﬁcation
In total 2864 proteins were identiﬁed using rank 1 peptides
at 1%FDR at peptide level (≥2 rank 1 peptides per protein ID).
Of the 2864 proteins 2628 (92%) had at least 1 unique peptide
sequence and 2009 (70%) proteins had only unique peptide
sequences. It was further observed that 236 (8%) proteins out s 1 ( 2 0 1 3 ) 38–47
of 2864 proteins had only shared peptide sequences. Of the
619 proteins with unique and shared peptides we  performed
quantiﬁcation using only unique peptides and compared
this quantiﬁcation to using the unique and shared peptides
and we  found a correlation of 0.99 when comparing the fold
change values from the two datasets (0.992 for spectral count-
ing and 0.999 for area under the curve). Thus, as there appears
to be no detrimental effect on accuracy using the shared and
unique peptides, compared to only unique peptides, and due
to the additional coverage gained by using shared and unique
peptides, we present results here obtained using shared
and unique peptide sequences from both spectral counting
and AUC forms of quantiﬁcation in the main text (Table 1,
Supplemental Table 1). All other results using only unique
peptide sequences for spectral counting and AUC methods
can be found in the supporting information (Supplemental
Tables 2–5, Supplemental Figs. 1–7).
3.2.  Protein  quantiﬁcation  and  hierarchical  clustering
We found 1072 proteins signiﬁcantly regulated in at least one
of the tissue type comparisons when using the area under
the curve dataset, while 611 proteins were signiﬁcantly reg-
ulated using the spectral counting dataset (in at least one of
the tissue type comparisons). Four hundred and sixty seven
proteins were found to be signiﬁcantly regulated in at least
one of the tissue type comparisons, as observed in both quan-
tiﬁcation methods (e.g. common to both spectral counting and
AUC; as seen in the Venn-Diagram in Fig. 2). PCA bi-plots using
area under the curve dataset (Fig. 3a) and spectral counting
dataset (Fig. 3b) for the 467 common proteins shows clear sep-
aration between tissue types/groups that consists of cells that
have common origin (additional information in Supplemen-
tal Figs. 1–4). Tissue types 1, 2 and 3 were all hepatocellular
in origin and tissue types 4–9 belonged to glandular epithe-
lium which clearly separated across two planes of the Bi-plot.
Within each bi-plot it can also be seen that all cases of nor-
mal  liver parenchyma (tissue type 1) are close to each other.
Hierarchical clustering (Fig. 4, additional information in Sup-
plemental Figs. 5–8) of the same 467 common proteins also
supported the results obtained using PCA which clusters hepa-
tocellular tissue types from glandular epithelium. It can be
observed that clustering of these 467 proteins (Fig. 4a and b)
based on Pearson’s correlation coefﬁcients and on protein data
matrix using normalized protein area values clustered sam-
ples that originated from tissue types 1, 8 and 9 within single
nested sub-groups. Although using spectral counting as a data
matrix produced similar results (Fig. 4c and d), it can be seen
that area under curve data matrix produced better separation
between groups when hierarchical clustering was performed.
Table 1 illustrates the number of differentially modulated pro-
teins that were common to both area under the curve and
spectral counting datasets per tissue type comparison.
3.3.  Difference  in  protein  expression  proﬁling  among  9
tissue types3.3.1.  Post-TACE  mixed  cancer
Although HCC and CC components of post-TACE cancer
are theoretically same in origin, these two areas showed
e u  p a o p e n p r o t e o m i c s 1 ( 2 0 1 3 ) 38–47 43
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Fig. 2 – Venn-Diagram showing comparison of the two
quantiﬁcation methods for proteins with unique and
shared peptides. Number of proteins found to be
signiﬁcantly modulated in each quantiﬁcation method and
those common to both, across all comparisons made in this
study.
signiﬁcantly different protein proﬁles as clearly demonstrated
by PCA and hierarchical clustering. In total 95 proteins were
shown to be signiﬁcantly modulated in the post-TACE HCC
regions compared to the CC regions. Among the 95 proteins,
60 (63%) were overlapped with molecules that were iden-
tiﬁed in the comparison between normal liver parenchyma
and bile duct (see below), in keeping with the hypothesis
that post-TACE cancers can show bilineage differentiation.
Seventy-eight proteins were found to be more  abundant in
HCC components, whereas 17 proteins were signiﬁcantly up-
regulated in CC areas. Two and ﬁve proteins showed signiﬁcant
difference between HCC components of post-TACE cancer and
conventional HCC, and between CC components of post-TACE
cancer and peripheral CC, respectively (Table 1). Names of
those proteins are available in Supplemental Table 1.
3.3.2.  Normal  liver  parenchyma  vs.  normal  bile  duct
Over 200 proteins were expressed at signiﬁcantly different
levels between normal liver and bile duct (Table 1). About a
half of those proteins were liver enzymes, which were more
abundantly present in normal liver parenchyma. In contrast,
proteins that were more  strongly expressed in normal bile
ducts were diverse, including keratins 7 and 19, annexins, and
galectins (Supplemental Table 1).
3.3.3.  Normal  liver  parenchyma  vs.  HCC
Among 11 proteins that showed statistically signiﬁcant differ-
ence between normal liver parenchyma and HCC, 5 proteins
(14-3-3 protein eta, Aldo-keto reductase family 1 member
B10 [AKR1B10], Heterogeneous nuclear ribonucleoprotein R,
Histone H1.5, Keratin type II cytoskeletal 6B) appeared over-
expressed in the cancer tissue. The remaining six, which were
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Fig. 3 – Principal component analysis (PCA) for identifying outliers and groups/clusters nested within the datasets. Each
small triangle represents the PC score along the ﬁrst two PC components for each sample. The naming convention of the
samples are: batch number tissue type number. PCA bi-plots illustrate that the three tissue types originating from
hepatocytes (tissue types 1–3) are separated from the rest, which are glandular epithelium in origin. Both PCA bi-plots show
ed frthat tissue type 1 (normal liver parenchyma) further separat
less abundant in HCC, were mostly liver enzymes supposed to
represent mature hepatocyte functions.
3.3.4.  Normal  bile  duct  vs.  peripheral  or  hilar  CC
Numbers of proteins that showed statistically signiﬁcant dif-
ference between normal and neoplastic bile ducts are 37 for
peripheral CC and 32 for hilar CC (Table 1, Supplemental Table
1). Six and eight proteins were signiﬁcantly overexpressed in
peripheral and hilar CC, respectively. Among them, 3 proteins
(Tubulin-beta 3 chain, Periostin, Collagen alpha-1(XII) chain)
were up-regulated in both types of CC. Fourteen proteins were
signiﬁcantly less abundant in both types of CCs.
3.3.5.  HCC  vs.  peripheral  CC
One hundred and sixty-ﬁve proteins showed statistically sig-
niﬁcant differences between these two types of cancers, which
develop in the liver parenchyma (Table 1, Supplemental Table
1). Most proteins that were overexpressed in HCC were liver
enzymes or mitochondrial proteins, whereas proteins that
were up-regulated in peripheral CC were diverse in func-
tion including cell–cell adhesion, cell migration, and signal
transduction. Multi-functional proteins such as annexins and
S100-A11 were also more  abundantly present in peripheral
CC. Ninety-six proteins (58%) were overlapped with proteins
that were identiﬁed in the comparison between normal liver
parenchyma and normal bile duct.
3.3.6.  Peripheral  CC  vs.  hilar  CC
These two types of CC are both adenocarcinoma of the bil-
iary epithelium in origin. Interestingly, 14 showed signiﬁcant
differences between peripheral and hilar CC. For example,
MUC5AC, a gastric type mucin, was signiﬁcantly more  abun-
dant in hilar CC, while Tenascin was upregulated in peripheral
CC.3.3.7.  PSC-associated  CC  vs.  hilar  CC
These two types of CC are histologically indistinguish-
able. But 5 proteins (Alpha-1B-glycoprotein, Asporin, Decorin,om the neoplastic hepatocellular specimens.
Methyl-CpG-binding protein 2, and Mimecan) were signiﬁ-
cantly different in abundance between PSC-associated and
conventional hilar CC. All of these were more  abundant in hilar
CC unrelated to PSC.
3.3.8.  Peripheral  or  hilar  CC  vs.  colorectal  metastasis
There were only 29 proteins expressed at signiﬁcantly differ-
ent levels in peripheral CC vs. colorectal metastasis and 63
proteins expressed at signiﬁcantly different levels in hilar CC
vs. colorectal metastasis (Table 1, Supplemental Table 1). Ker-
atin 20, which is the most commonly used intestinal marker in
routine pathological examination, did not reach to statistical
signiﬁcance.
3.4.  Volcano  plots  and  IHC
Two proteins (AKR1B10 and Tubulin-beta 3 chain) were inves-
tigated further by Volcano plots and IHC as a validation study.
The reason we chose AKR1B10 is that AKR1B10 was signiﬁ-
cantly upregulated in HCC than in normal liver or peripheral
CC, suggesting that this may become a diagnostic marker spe-
ciﬁc to HCC. The reason for Tubulin-beta 3 is that this protein
was signiﬁcantly up-regulated in peripheral CC than in either
tissue type of normal liver, HCC, or normal bile duct, sug-
gesting Tubulin-beta 3 to have a diagnostic value speciﬁc to
peripheral CC. We  focused on four tissue types: normal liver
parenchyma, HCC, normal bile duct, and peripheral CC, as they
are clinically most important to differentiate.
The Volcano plots (Fig. 5a) suggested up regulation of
AKR1B10 (O60218) in HCC (tissue type 2) as statistically sig-
niﬁcant (p-value 2.83E−02 and log 2 fold change 2.95) when
compared to normal liver parenchyma (tissue type 1) using
area data matrix for quantiﬁcation. AKR1B10 was also found
to be up-regulated in normal bile duct (tissue type 9) when
compared to normal liver parenchyma. While Tubulin-beta 3
chain (Q13509) was found to up-regulated in peripheral CC (tis-
sue type 5) when compared to normal liver parenchyma or
normal bile duct.
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Fig. 4 – Heat maps obtained after agglomerative hierarchical clustering. The naming convention of the samples is batch
number tissue type number. Again, similarly to PCA we  see clustering of tissue types of hepatocellular origin and glandular
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On immunostaining, AKR1B10 was only focally expressed
n normal liver, while this was more  diffusely positive in HCC
Fig. 5b). AKR1B10 was also moderately expressed in cirrhotic
iver (background of HCC), suggesting this to be up-regulated at
he early stage of multi-step hepato-carcinogenesis. AKR1B10
as diffusely positive in normal bile duct, and patchily posi-
ive in peripheral CC, in keeping with the proteomics results
Supplemental Table 1). Tubulin-beta 3 chain was completely
egative in normal liver, HCC, and normal bile duct, while it
as diffusely expressed in 5 of 7 cases of peripheral CC (Fig. 5b).
.  Discussion
e  have shown that the combination of laser microdissec-
ion and LC–MS/MS proteomics is a powerful approach which
llows extensive proﬁling of protein expression in selected
umor sub-populations. This technique can be relatively easily
pplied to FFPE histological archival material, a major advan-
age in the design of both prospective and retrospective tissuebased studies. The identiﬁcation of proteins already known
to be speciﬁc to certain lineages (e.g. keratins 7 and 19 in bil-
iary epithelium [21]), supports the robustness of the technique.
In this study we have identiﬁed sets of proteins speciﬁc to
well characterized hepato-biliary lineages and their neoplas-
tic counterparts, and which could be used as biomarkers with
diagnostic and prognostic potential, therapeutic targets or to
understand the underlying carcinogenetic processes.
The identiﬁcation of protein sets speciﬁc to the hepato-
cellular and cholangiocellular phenotype of post-TACE mixed
tumors, and their similarity to their normal and typical neo-
plastic counterparts conﬁrms that the differentiation process
is truly divergent, despite a probable origin from a common
progenitor. Further studies are necessary to help under-
stand the molecular mechanisms behind this transition. Of
equal importance is the identiﬁcation of proteins differentially
expressed between normal and neoplastic hepatocytes and
biliary epithelial cells, as they could provide markers of malig-
nant transformation or tumor differentiation; and between
HCC and peripheral CC, which often overlap in both clinical
46  e u  p a o p e n p r o t e o m i c s 1 ( 2 0 1 3 ) 38–47
Fig. 5 – Validation of protein up-regulation through Volcano plots and IHC. (a) Volcano plots for AKR1B10: upper left
panel–normal liver parenchyma vs. HCC; upper right panel – normal liver parenchyma vs. normal bile duct. Volcano plots
for Tubulin-beta 3 chain: lower left panel–normal liver parenchyma vs. peripheral CC; lower right panel – peripheral CC vs.
normal bile duct. (b) On IHC, AKR1B10 is diffusely expressed in HCC, while its expression is only patchy or weak in normal
liver parenchyma and peripheral CC. AKR1B10 is also diffusely positive in normal bile duct. Immunostaining for
Tubulin-beta 3 chain on normal liver, HCC, normal bile duct, and peripheral CC. The expression of Tubulin-beta 3 chain
appears to be speciﬁc for peripheral CC.
presentation, and appearance on imaging and histology
[22,23]. Of note alpha-fetoprotein (AFP), a marker commonly
increased in the serum of patients with HCC [2], was not iden-
tiﬁed in any tissue type in this study. This is probably due to
expression levels in tissue samples being below the LC–MS/MS
detection threshold. Serum AFP levels are known to be ele-
vated in about 75% of patients with HCC, but its expression in
tissue is detectable in than 40% of patients even by IHC [24,25].
Interestingly one of the ﬁve proteins (14-3-3 protein eta)
shown to be signiﬁcantly over-expressed in HCC compared to
normal liver parenchyma is known to play a role in mecha-
nisms known to contribute to the cancer phenotype, as the
abnormal expression of 14-3-3 protein eta has been reported
in some human neoplasms [26,27]. Another two (Hetero-
geneous nuclear ribonucleoprotein R and Histone H1.5) are
involved in gene transcription through chromatin remodel-
ing, DNA methylation, and processing of precursor mRNA  in
the nucleus. Our study also identiﬁed AKR1B10 as a signiﬁ-
cantly up-regulated protein in HCC, which was validated by
additional IHC. This ﬁnding is in keeping with a previous
study, where a random-based gene ﬁshing approach iden-
tiﬁed AKR1B10 as a signiﬁcantly up-regulated gene in HCC
compared to non-neoplastic liver tissue [28].We  were also interested in molecules that were speciﬁcally
up-regulated in CCs. Three proteins (Tubulin-beta 3 chain,
Periostin, Collagen alpha-1(XII) chain) were up-regulated in
CC compared to normal bile duct. Tubulin-beta 3 is the majorconstituent of microtubules and plays a critical role in
proper axon guidance and maintenance. Periostin induces cell
attachment and spreading and plays a role in cell adhesion.
Collagen alpha-1(XII) interacts with type I collagen-containing
ﬁbrils, which are known to be overexpressed in invasive breast
carcinoma [11]. Increased deposition and aberrant cross-
linking of collagen is associated with the development of
invasive breast cancer, the result of which contributes to stiff-
ening of the extracellular matrix and is a factor that has been
shown to drive progression of in situ disease [11]. The over-
expression of these three proteins in CCs, and their known
functional roles in biology and pathology suggest they may be
useful markers of CC.
The three types of CCs are histologically very similar. Only
a small number of markers that show signiﬁcant difference
in abundance between peripheral and hilar CCs have been
identiﬁed [29]. This study identiﬁed 5 such proteins, which
may represent different underlying carcinogenetic processes.
PSC-associated CC is supposedly different from conventional
CC in underlying molecular events. However, these two types
of CCs are histologically almost identical with no reliable
molecular discriminators. No oncogenes or tumor suppressor
genes speciﬁcally involved in PSC-associated carcinogene-
sis have been identiﬁed to the best of our knowledge. This
study identiﬁed 5 signiﬁcantly modulated proteins between
these two tissue types, all less abundant in PSC-associated
CC.
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In conclusion, we  have shown that the combination of laser
icrodissection and LC–MS/MS allows comprehensive pro-
eomic proﬁling of tumor cell subpopulations and is applicable
o FFPE archival tissue. We  conﬁrm that mixed phenotype
ost-TACE HCC is composed of divergent hepatocellular and
holangiocellular lineages similar to their normal and typical
eoplastic counterpart. We  have identiﬁed potential biomark-
rs to be used in the distinction between non-neoplastic and
eoplastic hepatocytes and biliary epithelial cells, to reﬁne
rading of tumor differentiation, in the differential diagnosis
f primary liver tumors, and to investigate the pathogenesis
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cknowledgments
hanks to Claudia Hoehle for technical assistance and Stefan
elzer for bioinformatics assistance.
unding
his work was funded by The Institute of Liver Studies King’s
ollege Hospital and Proteome Sciences plc.
ppendix  A.  Supplementary  data
upplementary material related to this article can be found,
n the online version, at doi:10.1016/j.euprot.2013.10.001.
 e  f  e  r  e  n  c  e  s
[1] Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO
classiﬁcation of tumours of the digestive system. 4th ed.
Lyom: IARC; 2010.
[2] El-Serag HB. Hepatocellular carcinoma. N Engl J Med
2011;365:1118–27.
[3] Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical
diagnosis and staging of cholangiocarcinoma. Nat Rev
Gastroenterol Hepatol 2011;8:512–22.
[4] Alison MR. Liver stem cells: implications for
hepatocarcinogenesis. Stem Cell Rev 2005;1:253–60.
[5] Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic
regulation of cancer stem cells in liver cancer: current
concepts and clinical implications. J Hepatol 2010;53:568–77.
[6] Zen C, Zen Y, Mitry RR, Corbeil D, Karbanová J, O’Grady J,
et  al. Mixed phenotype hepatocellular carcinoma after
transarterial chemoembolization and liver transplantation.
Liver Transpl 2011;17:943–54.
[7] Aebersold R, Mann M. Mass spectrometry-based proteomics.
Nature 2003;422:198–207.
[8] Ong SE, Mann M. Mass spectrometry-based proteomics
turns quantitative. Nat Chem Biol 2005;1:252–62.
[9] Shi SR, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction
from formalin-ﬁxed, parafﬁn-embedded tissue sections:
quality evaluation by mass spectrometry. J Histochem
Cytochem 2006;54:739–43.
[10] Krizman DB, Burrows J. Use of formalin-ﬁxed,
parafﬁn-embedded tissue for proteomic biomarker
discovery. Proteomics for biomarker discovery: methods and
protocols. Methods Mol Biol 2013;1002:85–92.
[11] Bateman NW, Sun M, Bhargava R, Hood BL, Darﬂer MM,
Kovatich AJ, et al. Differential proteomic analysis of 1 ( 2 0 1 3 ) 38–47 47
late-stage and recurrent breast cancer from formalin-ﬁxed
parafﬁn-embedded tissues. J Proteome Res
2011;10(3):1323–32.
[12] Patel V, Hood BL, Molinolo AA, Lee NH, Conrads TP, Braisted
JC,  et al. Proteomic analysis of laser-captured
parafﬁn-embedded tissues: a molecular portrait of head and
neck cancer progression. Clin Cancer Res 2008;14(4):1002–14.
[13] Azimzadeh O, Scherthan H, Yentrapalli R, Barjaktarovic Z,
Uefﬁng M, Conrad M, et al. Label-free protein proﬁling of
formalin-ﬁxed parafﬁn-embedded (FFPE) heart tissue
reveals immediate mitochondrial impairment after ionising
radiation. J Proteomics 2012;75(8):2384–95.
[14] Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B.
Quantitative mass spectrometry in proteomics: a critical
review. Anal Bioanal Chem 2007;389:1017–31.
[15] Liu H, Sadygov RG, Yates 3rd JR. A model for random
sampling and estimation of relative protein abundance in
shotgun proteomics. Anal Chem 2004;76:4193–201.
[16] Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R,
Burroughs AK, et al., EASL Panel of Experts on HCC. Clinical
management of hepatocellular carcinoma. Conclusions of
the Barcelona-2000 EASL conference. European Association
for the Study of the Liver. J Hepatol 2001;35:421–30.
[17] Kettaneh N, Berglund S, Wold S. PCA and PLS with very large
data sets. Comput Stat Data Anal 2005;48:69–85.
[18] Bar-Joseph Z, Gifford DK, Jaakkola TS. Fast optimal leaf
ordering for hierarchical clustering. Bioinformatics
2001;17(Suppl. 1):S22–9. PMID: 11472989.
[19] Cui X, Churchill GA. Statistical tests for differential
expression in cDNA microarray experiments. Genome Biol
2003;4:210.
[20] Best CJM, Gillespie JW,  Yi Y, Chandramouli GVR, Perlmutter
MA, Gathright Y, et al. Molecular alterations in primary
prostate cancer after androgen ablation therapy. Clin Cancer
Res 2005;11:6823–34.
[21] Chu PG, Weiss LM. Keratin expression in human tissues and
neoplasms. Histopathology 2002;40:403–39.
[22] Vilana R, Forner A, Bianchi L, García-Criado A, Rimola J, de
Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma
in  cirrhosis patients may display a vascular pattern similar
to  hepatocellular carcinoma on contrast-enhanced
ultrasound. Hepatology 2010;51:2020–9.
[23] Sempoux C, Jibara G, Ward SC, Fan C, Qin L, Roayaie S, et al.
Intrahepatic cholangiocarcinoma: new insights in pathology.
Semin Liver Dis 2011;31:49–60.
[24] Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, et al. Value of
-fetoprotein in association with clinicopathological
features of hepatocellular carcinoma. World J Gastroenterol
2013;19:1811–9.
[25] Porcell AI, De Young BR, Proca DM, Frankel WL.
Immunohistochemical analysis of hepatocellular and
adenocarcinoma in the liver: MOC31 compares favorably
with other putative markers. Mod Pathol 2000;13:773–8.
[26] Wang Z, Nesland JM, Suo Z, Trope CG, Holm R. The
prognostic value of 14-3-3 isoforms in vulvar squamous cell
carcinoma cases: 14-3-3 and  are independent prognostic
factors for these tumors. PLoS ONE 2011;6:e24843.
[27] Yang X, Cao W,  Lin H, Zhang W,  Lin W, Cao L, et al.
Isoform-speciﬁc expression of 14-3-3 proteins in human
astrocytoma. J Neurol Sci 2009;276:54–9.
[28] Heringlake S, Hofdmann M, Fiebeler A, Manns MP,
Schmiegel W,  Tannapfel A. Identiﬁcation and expression
analysis of the aldo-ketoreductase1-B10 gene in primary
malignant liver tumours. J Hepatol 2010;52:220–7.et  al. Comparative protein expression proﬁles of hilar and
peripheral hepatic cholangiocarcinomas. J Hepatol
2009;51:93–101.
